Compare Stocks → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ANIXNASDAQ:GTHXNASDAQ:NKTRNASDAQ:YMAB Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIXAnixa Biosciences$3.18+3.6%$3.38$2.75▼$5.13$101.44M0.84140,294 shs356,961 shsGTHXG1 Therapeutics$3.99-4.8%$3.69$1.08▼$5.00$208.40M1.731.30 million shs343,795 shsNKTRNektar Therapeutics$1.38-2.8%$1.00$0.41▼$1.75$253.40M0.92.16 million shs958,001 shsYMABY-mAbs Therapeutics$15.29-0.3%$15.79$4.60▼$20.90$669.40M0.74402,252 shs158,213 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIXAnixa Biosciences+1.99%-3.15%-11.27%-35.77%-37.35%GTHXG1 Therapeutics+2.20%+2.70%+4.75%+13.86%+57.52%NKTRNektar Therapeutics+4.41%-4.70%+55.45%+181.02%+76.18%YMABY-mAbs Therapeutics+1.19%+1.32%-5.48%+61.64%+159.56%The system that called 2023’s top 7 stocks is at it again… (Ad)Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANIXAnixa Biosciences1.9689 of 5 stars3.53.00.00.01.03.30.0GTHXG1 Therapeutics3.5866 of 5 stars3.32.00.03.82.90.80.6NKTRNektar Therapeutics3.8696 of 5 stars3.05.00.04.20.02.50.6YMABY-mAbs Therapeutics0.3434 of 5 stars1.21.00.00.01.34.20.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIXAnixa Biosciences3.00Buy$12.00277.36% UpsideGTHXG1 Therapeutics2.50Moderate Buy$9.33133.92% UpsideNKTRNektar Therapeutics2.00Hold$3.50153.62% UpsideYMABY-mAbs Therapeutics2.33Hold$16.578.38% UpsideCurrent Analyst RatingsLatest ANIX, YMAB, GTHX, and NKTR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024GTHXG1 TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.003/21/2024ANIXAnixa BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.003/6/2024NKTRNektar TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$0.50 ➝ $1.003/6/2024YMABY-mAbs TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $22.003/5/2024NKTRNektar TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform3/4/2024YMABY-mAbs TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $26.003/4/2024YMABY-mAbs TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$16.00 ➝ $26.002/28/2024GTHXG1 TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$4.00 ➝ $5.002/28/2024GTHXG1 TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.002/20/2024YMABY-mAbs TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $21.002/13/2024ANIXAnixa BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIXAnixa Biosciences$210K483.06N/AN/A$0.75 per share4.24GTHXG1 Therapeutics$82.51M2.53N/AN/A$0.68 per share5.87NKTRNektar Therapeutics$90.12M2.81N/AN/A$0.69 per share2.00YMABY-mAbs Therapeutics$84.82M7.89N/AN/A$2.32 per share6.59Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIXAnixa Biosciences-$9.81M-$0.34N/AN/AN/AN/A-44.09%-40.90%6/12/2024 (Estimated)GTHXG1 Therapeutics-$47.97M-$0.95N/AN/AN/A-58.13%-106.04%-33.99%5/1/2024 (Confirmed)NKTRNektar Therapeutics-$276.06M-$1.46N/AN/AN/A-306.31%-96.80%-37.17%5/14/2024 (Estimated)YMABY-mAbs Therapeutics-$21.43M-$0.49N/AN/AN/A-25.26%-20.72%-16.28%5/13/2024 (Estimated)Latest ANIX, YMAB, GTHX, and NKTR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2024N/AGTHXG1 Therapeutics-$0.19N/A+$0.19N/AN/AN/A 3/12/2024Q1 2024ANIXAnixa Biosciences-$0.09-$0.10-$0.01-$0.10N/AN/A3/4/202412/31/2023NKTRNektar Therapeutics-$0.21-$0.22-$0.01-$0.22$17.09 million$23.89 million 2/29/2024Q4 2023YMABY-mAbs Therapeutics-$0.19-$0.02+$0.17-$0.02$21.72 million$23.36 million2/28/202412/31/2023GTHXG1 Therapeutics-$0.27-$0.21+$0.06-$0.21$12.83 million$14.87 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIXAnixa BiosciencesN/AN/AN/AN/AN/AGTHXG1 TherapeuticsN/AN/AN/AN/AN/ANKTRNektar TherapeuticsN/AN/AN/AN/AN/AYMABY-mAbs TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIXAnixa BiosciencesN/A15.1915.19GTHXG1 Therapeutics1.463.873.45NKTRNektar TherapeuticsN/A6.456.14YMABY-mAbs TherapeuticsN/A5.525.27OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIXAnixa Biosciences29.13%GTHXG1 Therapeutics24.21%NKTRNektar Therapeutics75.88%YMABY-mAbs Therapeutics70.85%Insider OwnershipCompanyInsider OwnershipANIXAnixa Biosciences22.60%GTHXG1 Therapeutics8.23%NKTRNektar Therapeutics3.07%YMABY-mAbs Therapeutics21.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableANIXAnixa Biosciences431.90 million24.69 millionOptionableGTHXG1 Therapeutics10052.23 million47.94 millionOptionableNKTRNektar Therapeutics137183.62 million177.98 millionOptionableYMABY-mAbs Therapeutics10043.78 million34.37 millionOptionableANIX, YMAB, GTHX, and NKTR HeadlinesSourceHeadlineY-mAbs Therapeutics (NASDAQ:YMAB) Shares Up 7%marketbeat.com - April 23 at 4:47 PMNew Strong Buy Stocks for April 19thzacks.com - April 19 at 7:50 AMY-mAbs Therapeutics (NASDAQ:YMAB) rises 9.6% this week, taking one-year gains to 161%finance.yahoo.com - April 18 at 1:21 PMNew Strong Buy Stocks for April 17thzacks.com - April 17 at 8:30 AMY-mAbs Therapeutics (NASDAQ:YMAB) & Dyne Therapeutics (NASDAQ:DYN) Critical Reviewamericanbankingnews.com - April 14 at 1:32 AMY-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 4%marketbeat.com - April 11 at 11:58 AMY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of "Hold" by Analystsmarketbeat.com - April 10 at 2:30 AMY-mAbs Therapeutics (NASDAQ:YMAB) Shares Down 3.3% marketbeat.com - April 9 at 11:46 AMY-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 3.2%marketbeat.com - April 3 at 3:27 PMY-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $16.19marketbeat.com - April 2 at 11:19 AMY-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 5.9%marketbeat.com - April 1 at 2:01 PMDenali Advisors LLC Sells 69,500 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)marketbeat.com - April 1 at 6:12 AMWall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Betzacks.com - March 28 at 10:56 AMY-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 3.9%marketbeat.com - March 26 at 12:38 PMYmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?zacks.com - March 20 at 8:40 AMY-mAbs Therapeutics Finance Chief Bo Kruse Resignsmarketwatch.com - March 15 at 8:31 AMY-mAbs Therapeutics, Inc.: Y-mAbs Therapeutics Announces Resignation of Chief Financial Officerfinanznachrichten.de - March 14 at 2:58 PMY-mAbs Therapeutics CFO Bo Kruse To Retiremarkets.businessinsider.com - March 14 at 9:57 AMY-mAbs Therapeutics Announces Resignation of Chief Financial Officerglobenewswire.com - March 14 at 9:05 AMWall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High?zacks.com - March 12 at 10:55 AMBAMF, Corewell Health partner on clinical trial for advanced cancer treatmentcrainsgrandrapids.com - March 11 at 3:17 PMCracking The Code: Understanding Analyst Reviews For Y-mAbs Therapeuticsmarkets.businessinsider.com - March 6 at 6:21 PMAre You Looking for a Top Momentum Pick? Why Y-mAbs Therapeutics, Inc. (YMAB) is a Great Choicezacks.com - March 5 at 1:01 PMY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 4 at 1:15 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAnixa BiosciencesNASDAQ:ANIXAnixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.G1 TherapeuticsNASDAQ:GTHXG1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.Nektar TherapeuticsNASDAQ:NKTRNektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.Y-mAbs TherapeuticsNASDAQ:YMABY-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.